Lexaria Bioscience Corp. Share Price

Equities

LEXX

US52886N4060

Pharmaceuticals

Market Closed - Nasdaq 01:30:00 27/04/2024 am IST 5-day change 1st Jan Change
2.35 USD +7.31% Intraday chart for Lexaria Bioscience Corp. +6.82% +88.00%
Sales 2024 * 482K 40.15M Sales 2025 * 488K 40.65M Capitalization 30.28M 2.52B
Net income 2024 * -6M -500M Net income 2025 * -7M -584M EV / Sales 2024 * 62.9 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 62.1 x
P/E ratio 2024 *
-4.39 x
P/E ratio 2025 *
-4.75 x
Employees 5
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.42%
More Fundamentals * Assessed data
Dynamic Chart
1 day+7.31%
1 week+6.82%
Current month-35.26%
1 month-36.66%
3 months+65.49%
6 months+102.59%
Current year+88.00%
More quotes
1 week
2.15
Extreme 2.15
2.45
1 month
1.85
Extreme 1.85
3.82
Current year
1.20
Extreme 1.2
6.85
1 year
0.65
Extreme 0.6488
6.85
3 years
0.65
Extreme 0.6488
12.50
5 years
0.65
Extreme 0.6488
33.00
10 years
0.65
Extreme 0.6488
76.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 26/06/26
President 53 15/15/15
Investor Relations Contact - 01/21/01
Members of the board TitleAgeSince
Chief Executive Officer 62 26/06/26
Director/Board Member 70 08/11/08
Director/Board Member 74 14/21/14
More insiders
Date Price Change Volume
26/24/26 2.35 +7.31% 172,106
25/24/25 2.19 -0.45% 22,122
24/24/24 2.2 -1.79% 98,910
23/24/23 2.24 -1.10% 53,986
22/24/22 2.265 +2.95% 34,458

Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST

More quotes
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.35 USD
Average target price
11 USD
Spread / Average Target
+368.09%
Consensus